Kristina M. Burow
Independent DirectorMs. Kristina M. Burow, M.B.A., is Director of Pretzel Therapeutics, Inc. Ms. Burow was Independent Director of Metsera, Inc. from May 2023 until November 13, 2025. Ms. Burow serves as Director at Mirador Therapeutics. She serves as Director and Board Observer at Interline Therapeutics, Inc. She serves as Director of Kisbee Therapeutics, Inc. She serves as Director at Treeline Biosciences, Inc. She serves as a Director at Pretzel Therapeutics and Epirium Bio. Ms. Burow serves as Co-Founder & Director of Orbital Therapeutics Inc. She serves as Board Member at Mirador Therapeutics, Inc. She serves as a Director at Autobahn Therapeutics, Inc. She served as Director of Remix Therapeutics Inc. until 2021. She had been Independent Director at Beam Therapeutics Inc. since June 2017 until June 05, 2024. Ms. Burow served as an Independent Director of Vir Biotechnology Inc. since December 2016 until August 28, 2020. She has been Director at ROME Therapeutics, Inc. She serves as Managing Director of Arch Venture Partners, L.P. since 2002. She has been the Managing Director of Arch Venture Fund VIII, L. P. since November 2011. Ms. Burow joined ARCH Venture Partners, L. P. in 2002 and served as its Associate since joining the firm in 2002, where she focuses on building innovative companies in the multiple areas including biotechnology, pharmaceuticals, alternative energy, health tech, ag-biotech, chemicals and specialty materials. She has played a significant role in the growth of ARCH’s life sciences portfolio, including multiple public companies. She previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. She had been an Independent Director of Gossamer Bio, Inc. since January 2018 until September 06, 2023. She has expertise in pharmaceuticals. Ms. Burow co-founded Receptos, Inc. in 2007. She served as Independent Director of Unity Biotechnology, Inc since November 2011 until March 31, 2022. She is co-Founder of Sapphire Energy, Inc. She joined ARCH from Novartis Venture Funds, where she was involved in numerous life science investments. She served as an Associate, Novartis Venture Fund at Novartis Venture Funds. She was a Co-Inventor of key technology platforms that formed the core of Kalypsys. She serves as a Member of the Board of Directors and an Observer of AgTech Accelerator. She served as Mindstrong Health, KYTHERA Biopharmaceuticals Incorporated (acquired by Allergan) and Ikaria, Incorporated (acquired by Mallinckrodt Pharmaceuticals). She has been a Director on the Board of Aledade and served as Director at AgBiome Inc. since April 11, 2013. She serves as a Member of the Board of Directors of Llama Therapeutics, Reactive Biosciences Inc. (formerly known as Boragen Inc.). She was a Director of Vividion Therapeutics, Inc. since January 2017 until 2022. She is listed under 2020 Midas Brink List by TrueBridge and Forbes. She had been a Director at Sienna Biopharmaceuticals, Inc. since October 2015. She serves as an Independent Director of Scholar Rock, Inc. since August 2014. Prior to joining ARCH, Ms. Burow was an associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spinouts from GNF. Ms. Burow served as an Independent Director at Metacrine, Inc. since May 2015 until February 10, 2022. She serves as Director of Architect Therapeutics, Inc. She serves as an Independent Director of Cenexys, Inc. Trelys, Inc. Lycera Corp. Limerick BioPharma, Inc. and Kilimanjaro Energy, Inc. She served as an Independent Director of Blackthorn Therapeutics, Inc. since 2013 until September 2020. She served as a Director of Receptos, Inc. from February 2010 to August 27, 2015. She served as a Director of Siluria Technologies, Inc. and Sapphire Energy, Inc. She serves as Board of Directors at Magnet Biomedicine. She served as Independent Director at Boundless Bio, Inc. since June 2019 until June 15, 2026 and serves as Director at Treeline Biosciences, Inc. She serves as Co-Founder and Independent Director since January 2020 at Neumora Therapeutics, Inc. She is a director of Scholar Rock (SRRK), Metsera (MTSR), Mirador Therapeutics, Architect Therapeutics, Autobahn Therapeutics, ROME Therapeutics, Pretzel Therapeutics, Treeline Biosciences and Magnet Biomedicine, among others. She previously was a co-founder and director of Receptos and a director at Beam Therapeutics (BEAM), Gossamer Bio (GOSS), Vir Biotechnology (VIR) and Vividion Therapeutics, among others. She directed chemistry operations and was active in business development where she helped create numerous companies as spinouts from GNF. Ms. Burow holds an M. B.A. from The University of Chicago Booth School of Business, an M. A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Positions
- Company NameScholar Rock Holding CorporationStock CodeSRRKPositionIndependent DirectorColleagues
- DLDavid L. HallalCEO & Chairman of the Board
- VSVikas SinhaCFO & Treasurer
- RKRobert Keith WoodsChief Operating Officer
- AKAkshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director
- EMErin MooreInterim Principal Financial & Accounting Officer
- KMKristina M. BurowIndependent Director
- JSJeffrey S. FlierIndependent Director & Member of Scientific Advisory Board
- JRJoshua ReedIndependent Director
- Company NameNeumora Therapeutics, Inc.Stock CodeNMRAPositionIndependent DirectorColleagues
